Altimmune (ALT) vs Emergent BioSolutions (EBS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Emergent BioSolutions (EBS) has outperformed Altimmune (ALT) over the past year, losing 49.7% versus a loss of 72.3%. Over five years, ALT leads with a -87.2% price change compared with -88.6% for EBS. Emergent BioSolutions is the larger company by market cap ($259.6 million vs $258.8 million), about 1.0 times the size, while Altimmune is growing revenue faster (+105.0% vs -28.8%).
Emergent BioSolutions converts more of its revenue into profit, with a net margin of 7.1% versus -214861.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALT | EBS |
|---|---|---|
| Share price | $1.33 | $5.05 |
| Market cap | $258.80M | $259.65M |
| 1-day change | -5.67% | -1.94% |
| YTD return | -63.16% | -59.14% |
| 1-year return | -72.35% | -49.70% |
| 5-year return | -87.24% | -88.58% |
| Forward P/E | — | 4.83 |
| EPS (TTM) | $-0.71 | $-5.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $41.00K | $742.90M |
| Revenue growth (YoY) | +105.00% | -28.81% |
| Net income (latest FY) | $-88.09M | $52.60M |
| Gross margin | — | 56.09% |
| Operating margin | -230460.98% | 13.47% |
| Net margin | -214860.98% | 7.08% |
| 52-week high | $6.44 | $14.06 |
| 52-week low | $1.32 | $4.36 |
| Distance from 52-week high | -79.35% | -64.08% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1127.82% | +98.02% |
| Average volume | 3.91M | 1.11M |
| Shares outstanding | 194.59M | 51.42M |
| Employees | 57 | 900 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EBS has outperformed ALT by 22.6 percentage points over the past year.
- Emergent BioSolutions is more profitable, keeping 7.1 cents of every revenue dollar as net income versus -214861.0 cents for Altimmune.
- Altimmune grew revenue faster in its latest fiscal year (+105.00% vs -28.81%).
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Emergent BioSolutions
EBS stock →Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 900 employees
ALT vs EBS FAQ
Which is bigger, Altimmune or Emergent BioSolutions?
Emergent BioSolutions (EBS) is larger, with a market capitalization of $259.65M compared with $258.80M for Altimmune (ALT).
Which stock has performed better over the past year, ALT or EBS?
EBS returned -49.70% over the past 12 months, compared with -72.35% for ALT (price return, excluding dividends). Past performance does not predict future results.
Are Altimmune and Emergent BioSolutions in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.